Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

194.20 +4.73 (+2.50%)

Streaming Delayed Price Updated: 1:58 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

60 61 Next >

Biogen Board Appoints Two New Independent Directors

September 12, 2024

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development

From Biogen Inc.

Via GlobeNewswire

Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know ↗

September 09, 2024

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.

Via Benzinga

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗

September 09, 2024

Via Benzinga

Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges ↗

September 09, 2024

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics...

Via Benzinga

Key Takeaways From Biogen Analyst Ratings ↗

September 04, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Biogen ↗

August 19, 2024

Via Benzinga

How Is The Market Feeling About Biogen? ↗

August 09, 2024

Via Benzinga

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder ↗

September 04, 2024

Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared...

Via Benzinga

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 04, 2024

From Biogen Inc.

Via GlobeNewswire

These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now ↗

August 31, 2024

This competitive showdown just saw one of the players hit a couple of bumps.

Via The Motley Fool

Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker ↗

August 28, 2024

Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

Via Benzinga

Biogen Earnings Flat; Biotech Giant Raises Guidance ↗

August 01, 2024

Sales slightly topped. Shares edged higher early Thursday.

Via Investor's Business Daily

The Analyst Verdict: Biogen In The Eyes Of 12 Experts ↗

July 29, 2024

Via Benzinga

Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential ↗

August 27, 2024

PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185.

Via Benzinga

Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety ↗

August 26, 2024

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed.

Via Benzinga

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗

August 22, 2024

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...

Via Benzinga

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. ↗

August 11, 2024

These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses.

Via The Motley Fool

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗

August 02, 2024

Apple and Meta had strong results, while AI spending remains robust.

Via Investor's Business Daily

Topics Artificial Intelligence

Biogen (BIIB) Q2 2024 Earnings Call Transcript ↗

August 01, 2024

BIIB earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? ↗

August 01, 2024

Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...

Via Benzinga

Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales ↗

August 01, 2024

Biogen reported Q2 adjusted EPS of $5.28, surpassing the $4.03 consensus. Sales were $2.47 billion, narrowly beating the $2.38 billion consensus. Notable changes include a 5% drop in multiple sclerosis...

Via Benzinga

Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November ↗

August 01, 2024

After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...

Via Benzinga

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)

July 30, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

July 30, 2024

From Biogen Inc.

Via GlobeNewswire

Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? ↗

July 29, 2024

Biogen stock has slipped 18% so far this year.

Via The Motley Fool

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗

July 26, 2024

The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...

Via Benzinga

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.